Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy.

ABSTRACT:

Purpose

The determinants of response or resistance to radioiodine (RAI) are unknown. We aimed to identify genomic and transcriptomic factors associated with structural responses to RAI treatment of metastatic thyroid cancer, which occur infrequently, and to test whether high MAPK pathway output was associated with RAI refractoriness.

Experimental design

Exceptional response to RAI was defined as reduction of tumor volume based on RECIST v1.1. We performed a retrospective case-control study of genomic and transcriptomic characteristics of exceptional responders (ER; n = 8) versus nonresponders (NR; n = 16) matched by histologic type and stage at presentation on a 1:2 ratio.

Results

ER are enriched for mutations that activate MAPK through RAF dimerization (RAS, class 2

SUBMITTER: Boucai L 

PROVIDER: S-EPMC10106408 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature